prof. dr. F. (Femke) van Wijk

prof. dr. F. (Femke) van Wijk

Full Professor
prof. dr. F. (Femke) van Wijk
  • Center for Translational Immunology (CTI) Research



Dr. van Wijk obtained her PhD on mechanisms of oral tolerance and allergic sensitization to peanut at the Utrecht University in 2006. After her first postdoctoral training in human immunology in the lab of Prof. B. Prakken at the UMCU she obtained a KNAW fellowship for a 2-year postdoc in the lab of Prof. H. Cheroutre in the La Jolla Institute for Immunology in La Jolla (USA) to work on tissue T cell adaptation . After being awarded a VENI personal fellowship, she moved to the UMCU to start her own research group. For her research on how antigen presenting cells sabotage T cell regulation in local inflammation van Wijk was awarded a prestigious ZonMw VIDI career development grant (2014), and in 2021 she received a ZonMw VICI grant for her work on naïve T cell imprinting and immune development. Her research program aims to elucidate tissue T cell responses in health and inflammation and to translate these insights into tools for (pre-clinical) disease monitoring and therapeutic targeting in chronic inflammatory diseases.  She takes a disease- and age-overarching approach to decipher common and specific pathogenic processes underlying different inflammatory conditions and one of her specific interests is early imprinting of disease. Diseases her group is working on include atopic dermatitis, inflammatory bowel disease, juvenile idiopathic arthritis, juvenile dermatomyositis and immune toxicity following immune therapy in cancer.

 Dr. van Wijk is the author of >100 publications in leading peer-reviewed journals and has extensive experience with national and international scientific advisory committees (NWO off-road program, samenwerkende gezondheidsfondsen PPS Immunology consortia, Sanofi type 2 innovation grant, EU Horizon 2020 REA-FET-OPEN and COFUND). She is participating in several international networks including T_CELL_CONNECT_EUROPE, Eureka Institute for Translational Medicine, and Understanding Childhood Arthritis Worldwide Network that are aimed at (international) exchanges and training of young scientists, knowledge sharing, and enhancing reproducibility of human data. In 2017 Dr. van Wijk received the PhD supervisor of the year award by the Utrecht University Graduate School of Life Sciences.

Dr. van Wijk is also manager research for the division paediatrics at the UMCU , and scientific director FOCIS (federation of clinical immunology societies) center of excellence.

Side Activities

2016-2017 Scientific review panel member “off-road” grant program, The Netherlands Organization of Scientific Research (NWO)

2017 Member of international advisory board new Allergy and Inflammation center Guangzhou Medical University, China (honorary)

2019 Scientific review panel member Sanofi Genzyme European innovation grant

2019 Scientific review panel member, Ørsted COFUND programme (co-funded by Marie Skłodowska-Curie Actions under H2020 )/ Technical University Denmark/ Denmark

2020 Scientific review panel member  H2020 FET-Open Challenging Current Thinking, the Enhanced European Innovation Council (EIC)

2021 Scientific review panel member The Research Foundation – Flanders (FWO)  TBM2021, Belgium

2018-current Member Utrecht Life Sciences Program Board, domain One Health (honorary)

2020 - current Scientific director FOCIS (federation of clinical immunology societies) center of excellence UMC Utrecht. (honorary)

2021-current Member scientific advisory committee "Samenwerkende Gezondheidsfondsen PPS Immunologie Consortia" (honorary)

2017-current Occasional consultant/speaker for Takeda, Johnson&Johnson, Janssen, Sanofi, Regeneron, VC lspvc 



Fellowship and Awards

ZonMw VICI (2021)

PhD Supervisor (co-promotor) of the year 2017, Graduate School of Life Sciences

Stimulerings Associate Professorship UMCU (2015)

ZonMw VIDI (2014)

ZonMw Veni (2010)

KNAW fellowship Ter Meulen Fund (2007)



Research Output (111)

Immunosuppression for immune-related adverse events during checkpoint inhibition:an intricate balance

Verheijden Rik J, van Eijs Mick J M, May Anne M, van Wijk Femke, Suijkerbuijk Karijn P M 12 May 2023, In: NPJ precision oncology. 7

Dupilumab in daily practice for the treatment of pediatric atopic dermatitis:28-week clinical and biomarker results from the BioDay registry

Kamphuis Esmé, Boesjes Celeste M., Loman Laura, Bakker Daphne S., Poelhekken Mila, Zuithoff Nicolaas P.A., Kamsteeg Marijke, Romeijn Geertruida L.E., van Wijk Femke, de Bruin-Weller Marjolein S., de Graaf Marlies, Schuttelaar Marie L.A. 5 Dec 2022, In: Pediatric Allergy and Immunology. 33

Regulatory T cells in psoriatic arthritis:an IL-17A-producing, Foxp3<sup>int</sup>CD161 + RORγt + ICOS + phenotype, that associates with the presence of ADAMTSL5 autoantibodies

Pouw J. N.Juliëtte, Nordkamp M. A.M.Michel Olde, van Kempen T. Tessa, Concepcion A. N.Arno, van Laar J. M.Jacob, van Wijk F. Femke, Spierings J. Julia, Leijten E. F.A.Emmerik, Boes M. Marianne Dec 2022, In: Scientific Reports. 12

Association of Serum Dupilumab Levels at 16 Weeks with Treatment Response and Adverse Effects in Patients with Atopic Dermatitis:A Prospective Clinical Cohort Study from the BioDay Registry

Spekhorst Lotte S., De Graaf Marlies, Loeff Floris, Zuithoff Nicolaas P.A., Bakker Daphne, Boesjes Celeste M., Thijs Judith, Achten Roselie, Van Wijk Femke, Rispens Theo, De Bruin-Weller Marjolein S. 2 Nov 2022, In: JAMA Dermatology. 158 , p. 1409-1413 5 p.

T cell interaction with activated endothelial cells primes for tissue-residency

Wienke Judith, Veldkamp Saskia R, Struijf Eva M, Yousef Yengej Fjodor A, van der Wal M Marlot, van Royen-Kerkhof Annet, van Wijk Femke 12 Sep 2022, In: Frontiers in Immunology. 13

Immune monitoring and treatment in immune-mediated inflammatory diseases

van Wijk Femke, de Bruin Marjolein, Leavis Helen, Nierkens Stefan 7 Jun 2022, In: Nature Communications. 13 , p. 1-1

Ocular surface disease is common in moderate-to-severe atopic dermatitis patients

Achten Roselie E, Bakker Daphne S, van Luijk Chantal M, van der Wal M Marlot, de Graaf Marlies, van Wijk Femke, Zuithoff Nicolaas P A, van der Rijst Lisa P, Boesjes Celeste M, Thijs Judith L, de Boer Joke H, de Bruin-Weller Marjolein S 16 Mar 2022, In: Clinical and Experimental Allergy. 52 , p. 801-805 5 p.

Analysing the protection from respiratory tract infections and allergic diseases early in life by human milk components:the PRIMA birth cohort

van Stigt Arthur H., Oude Rengerink Katrien, Bloemenkamp Kitty W.M., de Waal Wouter, Prevaes Sabine M.P.J., Le Thuy My, van Wijk Femke, Nederend Maaike, Hellinga Anneke H., Lammers Christianne S., den Hartog Gerco, van Herwijnen Martijn J.C., Garssen Johan, Knippels Léon M.J., Verhagen Lilly M., de Theije Caroline G.M., Lopez-Rincon Alejandro, Leusen Jeanette H.W., Van't Land Belinda, Bont Louis, 14 Feb 2022, In: BMC Infectious Diseases. 22

Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

Spekhorst Lotte S, Bakker Daphne, Drylewicz Julia, Rispens Theo, Loeff Floris, Boesjes Celeste M, Thijs Judith, Romeijn Geertruida L E, Loman Laura, Schuttelaar Marie-Louise, van Wijk Femke, de Graaf Marlies, de Bruin-Weller Marjolein S 2022, In: Allergy. 77 , p. 3398-3407 10 p.

Human regulatory T cells locally differentiate and are functionally heterogeneous within the inflamed arthritic joint

Lutter Lisanne, van der Wal M Marlot, Brand Eelco C, Maschmeyer Patrick, Vastert Sebastiaan, Mashreghi Mir-Farzin, van Loosdregt Jorg, van Wijk Femke 2022, In: Clinical & translational immunology. 11

All research output

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht





Practical maakt gebruik van cookies

Deze website maakt gebruik van cookies Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Wij plaatsen zelf ook cookies om onze site te verbeteren.

Lees meer over het cookiebeleid

Akkoord Nee, liever niet